Showing results (91-100 of 101) with videos related to
Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2017
The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future ApplicationsKenneth C Anderson, Daniel Auclair, Gary J Kelloff, et al.Journal of the National Cancer Institute|April 28, 2020
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot StudyBarbara A Conley, Lou Staudt, Naoko Takebe, et al.Journal of the National Cancer Institute|January 11, 2020
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial DesignKeith T Flaherty, Robert Gray, Alice Chen, et al.The Lancet. Haematology|June 17, 2018
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Frederic Baron, et al.The Lancet. Haematology|April 28, 2022
Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignanciesGita Thanarajasingam, Lori M Minasian, Vishal Bhatnagar, et al.The New England Journal of Medicine|July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.Cancer Cell|November 20, 2020
Molecular Features of Cancers Exhibiting Exceptional Responses to TreatmentDavid A Wheeler, Naoko Takebe, Toshinori Hinoue, et al.The New England Journal of Medicine|October 16, 2024
Nivolumab+AVD in Advanced-Stage Classic Hodgkin's LymphomaAlex F Herrera, Michael LeBlanc, Sharon M Castellino, et al.Blood Reviews|September 13, 2023
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)Maximilian Stahl, Jan Philipp Bewersdorf, Zhuoer Xie, et al.Blood|March 27, 2025
Reducing clinical trial eligibility barriers for patients with MDS: an icMDS position statementUma Borate, Kelly Pugh, Allyson Waller, et al.Pageof 11